Comparative Pharmacology
Head-to-head clinical analysis: DECASPRAY versus NASACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECASPRAY versus NASACORT.
DECASPRAY vs NASACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Decaspray contains dexamethasone, a potent synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene transcription. This results in anti-inflammatory and immunosuppressive effects through inhibition of phospholipase A2, reduction of prostaglandin and leukotriene synthesis, suppression of cytokine production, and decreased capillary permeability.
Triamcinolone acetonide, a corticosteroid, exerts anti-inflammatory effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production, thereby decreasing nasal inflammation.
2-4 metered sprays (400-800 mcg) intranasally twice daily. Maximum 8 sprays (1600 mcg) per day.
110 mcg (2 sprays) per nostril once daily; maximum: 440 mcg (4 sprays) per nostril once daily. Intranasal administration.
None Documented
None Documented
The terminal elimination half-life is approximately 3-4 hours in adults. This short half-life is consistent with its classification as a long-acting glucocorticoid due to high potency and prolonged tissue effects, not extended plasma presence.
Terminal elimination half-life is approximately 3-4 hours after intranasal administration; however, due to prolonged residence time in nasal mucosa, clinical effects persist beyond plasma half-life.
Decaspray (dexamethasone) is primarily metabolized in the liver, with less than 10% excreted unchanged in urine. Minor biliary excretion occurs, but fecal elimination is negligible. Overall, renal excretion accounts for >90% as metabolites, with <10% as parent drug.
Primarily hepatic metabolism via CYP3A4; renal excretion accounts for <5% of unchanged drug; biliary/fecal excretion of metabolites accounts for ~60% of total clearance.
Category C
Category C
Intranasal Corticosteroid
Intranasal Corticosteroid